![5 Decades of Impact reflection series – Australasian Leukaemia and Lymphoma Group](https://oncodaily.com/pub/uploads/2023/10/Australasian-Leukaemia-and-Lymphoma-Group1-e1698762160372-1280x1205.jpg)
5 Decades of Impact reflection series – Australasian Leukaemia and Lymphoma Group
Australasian Leukaemia and Lymphoma Group (ALLG) shared on their LinkedIn:
“To mark the start of our 50-year celebration Scientific Meeting in Sydney this week, we are highlighting key improvements in the disease since the ALLG‘s inception by launching our 5 Decades of Impact reflection series.
First, we are focusing on Lymphoma. Did you know in 2023, many patients with Lymphoma are cured or have a near-normal life expectancy?
This wasn’t always the case.
In 1989, 78% of all persons diagnosed with Hodgkin lymphoma survived five years after diagnosis. This survival rate is now more than 90% and for older adults it has risen from 46% to 70%.
It’s thanks to the great work of the ALLG community and the leaders and members of our Lymphoma Scientific Working Party that these breakthroughs were made possible.
Read more of our 5 Decades of Impact stories here and look forward to more from ours series tomorrow and throughout the week.”